Such results collectively indicate that cIAP inhibition blocks early events in CD137 signaling and, together, provide evidence for a role of cIAPs in the signal transduction that can be elicited by infusion of agonist anti-human CD137 mAbs such as those used for cancer immunotherapy purposes. Here, TNFRSF9 is linked to cancer.